Literature DB >> 8127113

Complications of neonatal extracorporeal membrane oxygenation. Collective experience from the Extracorporeal Life Support Organization.

J B Zwischenberger1, T T Nguyen, J R Upp, P E Bush, C S Cox, T Delosh, L Broemling.   

Abstract

Since 1973, 7667 neonates have been treated with extracorporeal membrane oxygenation for severe respiratory failure and their cases reported to the Extracorporeal Life Support Organization Registry. The overall survival was 81% in these neonates, who were thought to have a survival of 20% without extracorporeal membrane oxygenation. A total of 4322 mechanical complications (0.56 +/- 0.84 per case) and 13,827 patient complications (1.80 +/- 2.12 per case) were reported overall. The most common mechanical complications included clots in the circuit (19%), cannula placement (9%), oxygenator failure (4%), and others (9%). Common patient complications included cardiopulmonary (43%), neurologic (35%), bleeding (35%), metabolic (32%), renal (25%), and renal (25%), and infectious (9%). From the initial experience to 1988 the average number of mechanical complications per case was 0.27 per case and this significantly increased during 1990 to 1992 to 0.75 per case (p < 0.05). Likewise, from 1973-1985 to 1988 the average patient complications per case were 1.44 per case and this significantly increased during 1990 to 1992 to 2.10 per case. During the same periods, patient survival significantly decreased from 84% (1973-1985 to 1988, n = 2463) to 80% (1990 to 1992, n = 4005). Venovenous double-lumen single cannula extracorporeal membrane oxygenation had a higher survival than venoarterial extracorporeal membrane oxygenation (91% versus 81%) and a lower rate of major neurologic complications. The incidence and survival with seizures (6% and 89% venovenous versus 13% and 61% venoarterial) or cerebral infarction (9% and 69% venovenous versus 14% and 46% venoarterial) was significantly lower with the venovenous method and appeared to have a substantial impact on overall survival. The correlation of patient complication rate and total complication rate with survival was highly significant, however, causality cannot be established. Explanations for the increase in complications, relative to a decrease in survival, despite a growing nationwide experience include (1) increased complexity of cases as many programs expand entry criteria (more premature infants, infants with grade 1 or 2 intracranial hemorrhage, and complex congenital diaphragmatic hernia), (2) a growing number of programs with fewer cases per program, yet greater accessibility, (3) less reluctance to report complications encountered during extracorporeal membrane oxygenation as group experience grows, and (4) changes in the Extracorporeal Life Support Organization data form to be more inclusive of more minor complications.

Entities:  

Mesh:

Year:  1994        PMID: 8127113

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  19 in total

1.  Meconium aspiration syndrome and extracorporeal membrane oxygenation.

Authors:  P J Davis; L S Shekerdemian
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-01       Impact factor: 5.747

2.  Hemolytic and thrombocytopathic characteristics of extracorporeal membrane oxygenation systems at simulated flow rate for neonates.

Authors:  Andrew D Meyer; Andrew A Wiles; Oswaldo Rivera; Edward C Wong; Robert J Freishtat; Khoydar Rais-Bahrami; Heidi J Dalton
Journal:  Pediatr Crit Care Med       Date:  2012-07       Impact factor: 3.624

3.  A multicenter international survey of renal supportive therapy during ECMO: the Kidney Intervention During Extracorporeal Membrane Oxygenation (KIDMO) group.

Authors:  Geoffrey M Fleming; David J Askenazi; Brian C Bridges; David S Cooper; Mathew L Paden; David T Selewski; Michael Zappitelli
Journal:  ASAIO J       Date:  2012 Jul-Aug       Impact factor: 2.872

4.  Reduced ventilator pressure and improved P/F ratio during percutaneous arteriovenous carbon dioxide removal for severe respiratory failure.

Authors:  S K Alpard; J B Zwischenberger; W Tao; D J Deyo; A Bidani
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

5.  Evaluation of a pumping assist lung that uses a rotating fiber bundle.

Authors:  Robert G Svitek; Brian J Frankowski; William J Federspiel
Journal:  ASAIO J       Date:  2005 Nov-Dec       Impact factor: 2.872

6.  Evaluation of Calcium Homeostasis and Dietary Supplementation for Pediatric and Neonatal Patients Receiving Extracorporeal Membrane Oxygenation Support.

Authors:  Marcus C Kaplan; Travis S Heath
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Jan-Feb

7.  Epidemiology of Stroke in Pediatric Cardiac Surgical Patients Supported With Extracorporeal Membrane Oxygenation.

Authors:  David K Werho; Sara K Pasquali; Sunkyung Yu; Janet Donohue; Gail M Annich; Ravi R Thiagarajan; Jennifer C Hirsch-Romano; Michael Gaies
Journal:  Ann Thorac Surg       Date:  2015-08-20       Impact factor: 4.330

8.  The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children.

Authors:  Enno D Wildschut; Annewil van Saet; Pavla Pokorna; Maurice J Ahsman; John N Van den Anker; Dick Tibboel
Journal:  Pediatr Clin North Am       Date:  2012-08-29       Impact factor: 3.278

9.  The Incidence of Acute Kidney Injury and Its Effect on Neonatal and Pediatric Extracorporeal Membrane Oxygenation Outcomes: A Multicenter Report From the Kidney Intervention During Extracorporeal Membrane Oxygenation Study Group.

Authors:  Geoffrey M Fleming; Rashmi Sahay; Michael Zappitelli; Eileen King; David J Askenazi; Brian C Bridges; Matthew L Paden; David T Selewski; David S Cooper
Journal:  Pediatr Crit Care Med       Date:  2016-12       Impact factor: 3.624

10.  Extracorporeal life support for neonatal respiratory failure. A 20-year experience.

Authors:  C J Shanley; R B Hirschl; R E Schumacher; M C Overbeck; T N Delosh; R A Chapman; A G Coran; R H Bartlett
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.